RBM10 and neoplasm: Considering the similarities between RBM5 and RBM10, and the recent finding that RBM10 is mutated in up to 21% of invasive lung adenocarcinomas [21], we hypothesized that RBM10 shares RBM5’s tumor-suppressor properties in SCLC.